(Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Novavax will ...
Shares of Novavax surged after the company disclosed a $1.4 billion licensing deal with Sanofi. The stock was up 72% at $7.66 in premarket trading on Friday. Shares are on track to open in ...
LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own. The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s ...
Shares of Novavax jumped as much as 50% as Wall Street cheered a new multibillion-dollar deal with French drugmaker Sanofi that kicked off a dramatic turnaround for the struggling vaccine maker.
Don’t call it a comeback: Novavax just (briefly) became a meme stock. The Maryland-based biotech joined the likes of Ango American, Vodafone and the notorious GameStop in a resurgence of the meme ...
Struggling Novavax struck a $1.4 billion deal with Sanofi on Friday to commercialize its existing COVID-19 vaccine and develop a combined jab to protect against both the coronavirus and influenza ...
Sanofi entered into a co-exclusive licensing agreement with Novavax to sell the biotech’s sell COVID-19 vaccine going forward and develop novel flu-COVID combination shots. As part of the deal ...
By Patrick Wingrove and Bhanvi Satija (Reuters) -Novavax on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi for its COVID-19 vaccine in exchange for a stake that ...
Sanofi will pay vaccine maker Novavax $500 million and take a small equity stake in the Maryland-based company as part of a broad COVID-19 shot alliance, the companies announced Friday. Through ...
Novavax (NVAX) shares are skyrocketing after announcing a $1.2 billion deal with Sanofi (SNY) to commercialize a combined COVID-19 and flu shot. Yahoo Finance's Anjalee Khemlani joins The Morning ...